Laboratory of Genetic Engineering and Recombinant Protein Expression

Main activities

• Molecular cloning of genes encoding viral antigens and biologically active substances in heterologous systems
• Construction of chimeric monoclonal antibodies; obtaining chimeric monoclonal antibody producers
• Development of technology for the isolation and purification of biopolymers
• Identification of biopolymers and assessment of their purity
• Drug stability study
• Study of pharmacokinetics and drug metabolism 

Achievements

•  “Transfer of foreign intellectual property (gene anti-tumor therapy drug based on components of the autophagy system) and conducting its pre-clinical and clinical studies” (Code ‘2.3 Autophagy 2012’, state contract 124411.1008799.13.129, July 09, 2012)
• "Uniflu" research and development: "Pre-clinical studies of recombinant influenza A vaccine based on the ectodomain of the viral M2 protein’ (Code ‘2.1 Influenza Vaccine 2013’)
• Pre-clinical studies of a mucosal universal influenza vaccine, based on attenuated influenza vectors featuring a modified NS1 gene, for the prevention of seasonal and pandemic influenza (state contract 14.N08.12.1043, August 28, 2015, in assoc. with the federal targeted program “Development of the Russian pharmaceutical and medical sector until 2020 and beyond” )
• Pre-clinical studies of a peptide-based antiviral drug that suppresses the replication of human influenza A (H1N1) virus
• Research and development: “Development of diagnostic systems for heightened pandemic preparedness, including the detection of Ebola and influenza viruses, at the patient’s location”
• Triazid: "Study of the safety, tolerability, and pharmacokinetics of the drug Triazide in healthy volunteers" (phase 1)

Epidemic Situation